General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Key performance indicators

Access1
Total patients reached (millions)2 1 229
Patients reached through access programs (millions) 72.4
People reached through training, health education and service delivery (millions) 10.2
Top 20 global burden of disease conditions addressed by products and pipeline3 100%

People and ethics
Resignations (including retirements) / separations / hiring (% of associates) 10% / 5% / 13%
Women in management: % of management4 / % of Board of Directors 40% / 18%
Associate nationalities / associate nationalities in management4 150 / 107
Lost-time injury and illness rate (per 200 000 hours worked)5 0.12
Misconduct cases reported / substantiated 1 699 / 930
Regulatory inspections without major findings 98.4%

Environmental sustainability6
Greenhouse gas emissions, total Scope 1 and Scope 2 (k tons) 1 557
Water discharge (million m3) 17.5


  1. See access table for additional detail
  2. 2014 and 2013 number not fully comparable to previous years due to methodology changes
  3. As defined by the US-based Institute for Health Metrics and Evaluation, excluding injuries
  4. Management defined locally
  5. Data include Novartis associates and third-party personnel managed by Novartis associates
  6. For more detail on environmental sustainability, see www.novartis.com/environmental-care